Traders should watch for the EB613 late-breaking oral presentation at ENDO 2026 on June 14. Positive data readout could be a significant catalyst given Entera's ~$59M market cap and lack of approved products. Risk remains that data may underwhelm or that timelines shift.
Price Chart
Executive Summary
Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clinical data supporting its EB613 osteoporosis candidate selected for a late-breaking oral presentation. This is a positive catalyst for a clinical-stage biotech because it validates the EB613 Phase 3 candidate selection with new data at a major medical conference, but no financial terms, approval decisions, or definitive guidance were provided.
Key Facts
- EB613 (oral PTH(1-34) for osteoporosis) new clinical data selected for Late Breaking Oral Presentation at ENDO 2026 (June 13-16, 2026).
- Abstract for EB613 titled 'Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study'.
- Pre-clinical results for EB612 (oral long-acting PTH(1-34) for hypoparathyroidism) and EB618 (oral dual GLP-1/glucagon agonist for obesity/metabolic disorders) also accepted.
- ENDO 2026 takes place June 13–16, 2026 in Chicago; EB613 late-breaking oral session is Sunday, June 14, 2026 at 3:30 PM CT.
- Entera is a clinical-stage company with no approved products; its most advanced candidate EB613 completed a Phase 2 study meeting primary and secondary endpoints.
Financial Impact
No financial data provided; market cap ~$59M. Positive pipeline milestone for early-stage biotech.
Risk Factors
- Clinical-stage company with no approved products — binary event risk around Phase 3 plans.
- Presentation is an abstract at a medical conference; data quality/impact unknown until release.
- Going concern and financing risk noted in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $2.84 | awaiting T+60 | — | $2.85 (+0.35%) |
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.85 (+2.89%) |
Oct 6, 2026 21d ago | 8-K | $2.53 | awaiting T+60 | — | $2.85 (+12.65%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.85 (−7.47%) |
Aug 18, 2026 10w ago | 8-K | $2.89 | awaiting T+60 | — | $2.85 (−1.38%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.85 (−6.25%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.85 (−5.00%) |
Jun 16, 2026 19w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.85 (+141.53%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.85 (+133.61%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.85 (+131.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers